A T Cohen
Affiliation: King's College London
- Applying risk assessment models in orthopaedic surgery: effective risk stratificationA T Cohen
Department of Medicine, King s College Hospital, London, UK
Blood Coagul Fibrinolysis 10:S63-70. 1999..Screening for clotting disorders and other additional risk factors may assist identification of very-high-risk patients and allow appropriate targeting of intensive prophylactic therapy...
- The significance of distal vein thrombosis and bilateral diseaseA T Cohen
Department of Surgery, Guy s, King s and St Thomas School of Medicine, Bessemer Road, London, UK
J Thromb Haemost 3:1360-1. 2005
- Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX studyRaza Alikhan
Academic Department of Surgery, Guy s, King s, St Thomas School of Medicine, London, UK
Blood Coagul Fibrinolysis 14:341-6. 2003..22 (95% CI, 0.09-0.51); immobility, 0.53 (95% CI, 0.14-1.72); previous VTE, 0.49 (95% CI, 0.15-1.68); and cancer, 0.50 (95%o CI, 0.14-1.72). The beneficial effects of enoxaparin extend to a wide range of acutely ill medical patients...
- Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patientsAlexander T Cohen
Vascular Medicine, Department of Surgery, Guy s, King s and St Thomas School of Medicine, London, UK
Thromb Haemost 94:750-9. 2005..These medical conditions and risk factors are included in a risk-assessment model which is hoped will provide a simple means of assisting clinicians in deciding whether thromboprophylaxis should be used in an individual patient...
- Are placebo-controlled trials ethical in areas where current guidelines recommend therapy? YesA T Cohen
Vascular Medicine Group, Vascular Department, King s College Hospital, London, UK
J Thromb Haemost 4:2130-2. 2006
- The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) studyAlexander T Cohen
Department of Haematological Medicine, King s College Hospital, London, United Kingdom Electronic address
Am Heart J 167:335-41. 2014....
- Managing pulmonary embolism from presentation to extended treatmentAlexander T Cohen
Department of Haematological Medicine, King s College Hospital, London, UK Electronic address
Thromb Res 133:139-48. 2014....
- NOACs for thromboprophylaxis in medical patientsAlexander Ander T Cohen
Vascular Medicine, Department of Surgery, King s College Hospital, London, UK
Best Pract Res Clin Haematol 26:183-90. 2013..This article briefly summarises our understanding of the background to preventing venous thromboembolism in hospitalised medical patients and reviews the details of the studies using NOACs. ..
- Rivaroxaban for thromboprophylaxis in acutely ill medical patientsAlexander T Cohen
Department of Vascular Surgery, King s College Hospital, London SE5 9RS, United Kingdom
N Engl J Med 368:513-23. 2013....
- Managing venous thromboembolism in Asia: winds of change in the era of new oral anticoagulantsAlexander Cohen
Vascular Medicine, King s College Hospital, London, United Kingdom
Thromb Res 130:291-301. 2012..Meanwhile, physicians should remain vigilant and strive to act early, decisively and appropriately to diagnose and treat VTE, particularly in patients at high risk...
- Long-term benefits of preventing venous thromboembolic eventsAlexander T Cohen
Surgery and Vascular Medicine, King s College Hospital, London, UK
Curr Med Res Opin 28:877-89. 2012..Newer oral anticoagulants such as rivaroxaban, dabigatran etexilate, apixaban and edoxaban, which do not have the limitations of established anticoagulants, have been developed...
- Thromboprophylaxis in non-surgical cancer patientsAlexander T Cohen
Vascular Medicine, Department of Vascular Surgery, King s College Hospital, London, UK
Thromb Res 129:S137-45. 2012..For ambulatory cancer patients undergoing chemotherapy we recommend LMWH or semuloparin. These are safe and effective agents in the thromboprophylaxis of non-surgical cancer patients...
- The use of rivaroxaban for short- and long-term treatment of venous thromboembolismAlexander T Cohen
King s College Hospital, Denmark Hill, London SE5 9RS, UK
Thromb Haemost 107:1035-43. 2012..Moreover, the simple, once-daily oral administration of rivaroxaban could potentially improve adherence to extended-duration VTE treatment compared with the current standard of care in individuals with confirmed DVT or PE...
- Thromboprophylaxis with dalteparin in medical patients: which patients benefit?Alexander T Cohen
Department of Surgery, King s College Hospital, Bessemer Road, London SE5 9PJ, UK
Vasc Med 12:123-7. 2007..Our findings, therefore, support the broad application of thromboprophylaxis in acutely ill hospitalized medical patients...
- Discoveries in thrombosis care for medical patientsAlexander T Cohen
Guy s, King s, St Thomas Academic Department of Surgery, London, United Kingdom
Semin Thromb Hemost 28:13-7. 2002..Low-molecular-weight heparin offers a safe and cost-effective alternative to unfractionated heparin in medical patients; to date, enoxaparin is the only low-molecular-weight heparin licensed for thromboprophylaxis in this indication...
- VTE prophylaxis for the medical patient: where do we stand? - a focus on cancer patientsAlexander T Cohen
Vascular Medicine, Department of Vascular Surgery, King s College Hospital, London, UK
Thromb Res 125:S21-9. 2010..There is no evidence for the use of aspirin, warfarin or mechanical methods. We recommend either low molecular weight heparin or fondaparinux as safe and effective agents in the thromboprophylaxis of medical patients...
- The use of graduated compression stockings in association with fondaparinux in surgery of the hip. A multicentre, multinational, randomised, open-label, parallel-group comparative studyA T Cohen
Department of Vascular Surgery, King s College Hospital, Bessemer Road, London SE5 9RS, UK
J Bone Joint Surg Br 89:887-92. 2007..88, 95% confidence interval 0.46 to 1.65, p = 0.69). Major bleeding occurred in only one patient. The addition of graduated compression stockings to fondaparinux appears to offer no additional benefit over the use of fondaparinux alone...
- Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortalityAlexander T Cohen
Vascular Medicine, Department of Surgery, King s College Hospital, London, SE5 9RS, UK
Thromb Haemost 98:756-64. 2007..Given the availability of effective VTE prophylaxis, many of these events and deaths could have been prevented. These results have important implications for the allocation of healthcare resources...
- Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional studyAlexander T Cohen
King s College Hospital, London, UK
Lancet 371:387-94. 2008....
- Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence?Alexander T Cohen
Honorary Consultant Vascular Physician, Vascular Medicine, King s College Hospital, London SE5 9RS, UK
Thromb Haemost 101:422-7. 2009..The advent of novel anticoagulants such as idraparinux with its long half-life offers hope for improved adherence with anticoagulation, and ultimately improved outcomes...
- Asia-Pacific Thrombosis Advisory Board consensus paper on prevention of venous thromboembolism after major orthopaedic surgeryAlexander T Cohen
King s College Hospital, London SE5 9RS, UK
Thromb Haemost 104:919-30. 2010..In conclusion, we call for recognition that VTE is an issue in Asian patients, and that effective thromboprophylaxis is the most important strategy...
- Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocolAlexander Thomas Cohen
Department of Surgery and Vascular Medicine, King s College Hospital, London SE59RS, UK
J Thromb Thrombolysis 31:407-16. 2011....
- Prophylaxis of venous thromboembolism in medical patientsA T Cohen
Academic Department of Surgery, Guy s, King s and St Thomas School of Medicine, Bessemer Road, London, SE5 9PJ, UK
Curr Opin Pulm Med 7:332-7. 2001..As the evidence accumulates and guidelines are strengthened physicians will be able to tailor the use of thromboprophylaxis to the individual patient's needs...
- Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trialAlexander T Cohen
Department of Surgery, Guy s, King s, and St Thomas s School of Medicine, London SE5 9PJ
BMJ 332:325-9. 2006..To determine the efficacy and safety of the anticoagulant fondaparinux in older acute medical inpatients at moderate to high risk of venous thromboembolism...
- Thromboprophylaxis in major abdominal surgery for cancerJ J Negus
Vascular Diseases Research Group, Guy s, King s and St Thomas School of Medicine, London SE5 9PJ, UK
Eur J Surg Oncol 32:911-6. 2006..To review the epidemiology and pathogenesis of venous thromboembolism (VTE) in surgical cancer patients, in addition to the use of thromboprophylaxis in major abdominal surgery, such as low-molecular-weight heparin (LMWH) and fondaparinux...
- Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX StudyRaza Alikhan
Academic Department of Surgery, Guy s, King s, and St Thomas School of Medicine, London, England
Arch Intern Med 164:963-8. 2004..There is limited information about risk factors for venous thromboembolism (VTE) in acutely ill hospitalized general medical patients...
- Meta-analysis of trials comparing ximelagatran with low molecular weight heparin for prevention of venous thromboembolism after major orthopaedic surgeryA T Cohen
Department of Surgery, Guy s, King s and St Thomas Hospital School of Medicine, London, UK
Br J Surg 92:1335-44. 2005..Use of low molecular weight heparin (LMWH) is standard practice for preventing postoperative venous thromboembolism (VTE). Ximelagatran is a new direct thrombin inhibitor for this indication...
- Pharmacological prevention of venous thromboembolism in medical patients at riskMia Wolozinsky
Academic Department of Surgery, King s College Hospital, London, UK
Am J Cardiovasc Drugs 5:409-15. 2005..We recommend either LMWH or fondaparinux sodium as well tolerated and effective thromboprophylactic agents in medical patients...
- Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trialA T Cohen
Academic Department of Surgery, Guy's, King's and St Thomas' School of Medicine, London, England, UK
Semin Hematol 38:31-8. 2001..Further studies are required to assess the benefit:risk ratio of therapy in other clearly-defined medical groups...
- Assessment of bleeding after concomitant administration of antiplatelet and anticoagulant agents in lower limb arthroplastyOla E Dahl
International Surgical Thrombosis Forum, Thrombosis Research Institute, London, UK
Pathophysiol Haemost Thromb 35:428-34. 2006..4-12 h) when compared with preoperative (12 h) administration of enoxaparin. Transfusion rates were significantly lower with administration of melagatran/ximelagatran compared with enoxaparin...
- Long-haul flights and deep vein thrombosis: a significant risk only when additional factors are also presentRoopen Arya
Department of Haematological Medicine, King s College Hospital, London, UK
Br J Haematol 116:653-4. 2002..3 (CI 0.6-2.8). Risk of DVT was only increased in long-haul travellers if one or more additional risk factors were present, with an odds ratio of 3.0 (CI 1.1-8.2). Such individuals may benefit from prophylactic measures to minimize risk...
- Fatal pulmonary embolism in hospitalised patients: a necropsy reviewR Alikhan
Department of Medicine, Royal United Hospital, Combe Park, Bath BA1 3NG, UK
J Clin Pathol 57:1254-7. 2004..To carry out a retrospective review of all postmortem reports during the period 1991 to 2000 at King's College Hospital, London, as an extension of a previous analysis performed for the period 1965 to 1990...
- Venous thromboembolism prophylaxis for the medical patient: where do we stand?Yshai Yavin
Vascular Medicine, Department of Vascular Surgery, King s College Hospital, London, UK
Semin Respir Crit Care Med 29:75-82. 2008..There is no evidence for the use of aspirin, warfarin, or mechanical methods. We recommend either low molecular weight heparin or fondaparinux as safe and effective agents in the thromboprophylaxis of medical patients...
- Venous thromboembolism risk and prophylaxis in the acute care hospital setting (ENDORSE survey): findings in surgical patientsAjay K Kakkar
Barts and the London School of Medicine and Dentistry, London, United Kingdom
Ann Surg 251:330-8. 2010..To evaluate venous thromboembolism (VTE) risk in patients who underwent a major operation, including the use of, and factors influencing, American College of Chest Physicians-recommended types of VTE prophylaxis...
- Risk factors for venous thromboembolism in orthopedic surgeryHtwe M Zaw
Vascular Diseases Research Group, Academic Department of Surgery, Guy s King s and St Thomas School of Medicine, London, UK
Isr Med Assoc J 4:1040-2. 2002
- Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancerDavid Bergqvist
Academic Hospital, Uppsala, Sweden
N Engl J Med 346:975-80. 2002..Abdominal surgery for cancer carries a high risk of venous thromboembolism, but the optimal duration of postoperative thromboprophylaxis is unknown...
- Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trialNils Kucher
Cardiovascular Division, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Arch Intern Med 165:341-5. 2005..We were concerned that a fixed rather than a weight-based dosing regimen of dalteparin sodium to prevent venous thromboembolism (VTE) might result in decreased efficacy in obese patients and decreased safety in elderly patients...
- Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United Marc F Botteman
International Health Economics, HERQuLES, Abt Associates Clinical Trials, Bethesda, Maryland 20814, USA
Clin Ther 24:1960-86; discussion 1938. 2002..The long-term clinical course after DVT can be further complicated by excess mortality, recurrent venous thromboembolism (VTE), and the post-thrombotic syndrome (PTS), which may produce sizable long-term economic burdens...
- Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United StatesJoseph A Caprini
Evanston Northwestern Healthcare, Evanston, IL, USA
Value Health 6:59-74. 2003..Estimates of the cost of long-term complications of a primary deep vein thrombosis (DVT), including the post-thrombotic syndrome (PTS) and recurrent venous thromboembolism (VTE), may be relevant for resource allocation decisions...
- Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacementBengt I Eriksson
Orthopaedics Department, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
Thromb Haemost 89:288-96. 2003..0%) and 306/1122 (27.3%) patients in the ximelagatran and enoxaparin group, respectively, a difference in risk of 3.7% in favour of enoxaparin (p = 0.053). Bleeding was comparable between the two groups...
- A safety analysis of thromboprophylaxis in acute medical illnessRaza Alikhan
Thromb Haemost 89:590-1. 2003
- Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX studyLouis Desjardins
Service hématologie, CHU Laval, Ste Foy, Quebec, Canada
Arch Pathol Lab Med 128:519-26. 2004..Plasma anti-Xa and anti-IIa activities correlate with the dose of low-molecular-weight heparin, and D-dimer and thrombin-antithrombin complexes are markers of procoagulant activity...
- Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patientsAlain Leizorovicz
Unite de Pharmacologie Clinique, Universite Claude Bernard Lyon I, Lyon, France
Circulation 110:874-9. 2004....
- Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolismFrederick A Anderson
Center for Outcomes Research, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
Am J Hematol 82:777-82. 2007..Given the existence of internationally-accepted evidence-based guidelines for prevention of VTE, research is required to establish if this patient population is receiving recommended VTE prophylaxis...
- Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patientsPaul T Vaitkus
Cardiology Division, College of Medicine, University of Illinois at Chicago, 840 S Wood St, Chicago, Illinois 60612, USA
Thromb Haemost 93:76-9. 2005..In conclusion, the high mortality rate in patients with asymptomatic proximal DVT underscores its clinical relevance and supports targeting of asymptomatic proximal DVT as an appropriate endpoint in clinical trials of thromboprophylaxis...